ScholarIQanswers from OpenAlex & ORCID
Stacie Hudgens
ResearcherPublications, citations & collaboration network
Stacie Hudgens is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Stacie Hudgens have?
ScholarIQindexed works
Stacie Hudgens has 171 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Stacie Hudgens have?
ScholarIQcitation count
Stacie Hudgens has 3,154 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Stacie Hudgens?
ScholarIQh-index
Stacie Hudgens has an h-index of 27 in OpenAlex.
What is the i10-index of Stacie Hudgens?
ScholarIQi10-index
Stacie Hudgens has an i10-index of 46 in OpenAlex.
What is the ORCID of Stacie Hudgens?
ScholarIQorcid
The ORCID for Stacie Hudgens is on the source record.
What is the OpenAlex record for Stacie Hudgens?
ScholarIQopenalex
The OpenAlex for Stacie Hudgens is on the source record.
What are the most-cited papers on Stacie Hudgens?
ScholarIQmost cited works
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
Youn H. Kim, M. Bagot, Lauren Pinter‐Brown, Alain H. Rook, Pierluigi Porcu, Sarah McCue Horwitz, Sean Whittaker, Y. Tokura, Maarten H. Vermeer, Pier Luigi Zinzani, Lubomir Sokol, Stephen Morris, Ellen J. Kim, Pablo L. Ortiz‐Romero, Herbert Eradat, Julia Scarisbrick, Athanasios Tsianakas, Craig A. Elmets, Stéphane Dalle, David C. Fisher, Ahmad Halwani, Brian Poligone, John P. Greer, Maria Teresa Fierro, Amit Khot, Alison J. Moskowitz, Amy Musiek, Andrei R. Shustov, Barbara Pro, Larisa J. Geskin, Karen M. Dwyer, Junji Moriya, Mollie Leoni, Jeffrey S. Humphrey, Stacie Hudgens, Dmitri O. Grebennik, Kensei Tobinai, Madeleine Duvic, Sunil Abhyankar, Oleg E. Akilov, Önder Alpdoğan, M. Beylot‐Barry, Erin Boh, Dolores Caballero, Richard Cowan, Brigitte Dréno, Reinhard Dummer, Timothy S. Fenske, Francine Foss, Noriko Fukuhara, Pratyush Giri, Koji Habe, Toshihisa Hamada, Kiyohiko Hatake, Shinsuke Iida, Osamu Ishikawa, Lars Iversen, Eiji Kiyohara, Hiroshi Koga, Neil J. Korman, Bryone J. Kuss, Zanetta S. Lamar, Frederick Lansigan, Mary Jo Lechowicz, Adam Lerner, Nina Magnolo, Lawrence A. Mark, Tomomitsu Miyagaki, Javier Muñoz, Jan P. Nicolay, Kaoru Nishiwaki, Hiroyuki Okamoto, Mikio Ohtsuka, Theresa Pacheco, Christiane Querfeld, Ronald Peter Rapini, Shigetoshi Sano, Maiko Tanaka, Michael D. Tharp, Jiro Uehara, Hidefumi Wada, Jillian Wells, Ryan A. Wilcox, Basem M. William, Kentaro Yonekura
Measuring the side effects of taxane therapy in oncology
David Cella, Amy H. Peterman, Stacie Hudgens, Kimberly Webster, Mark A. Socinski
Quality of Life in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia on Imatinib Versus Interferon Alfa Plus Low-Dose Cytarabine: Results From the IRIS Study
Elizabeth A. Hahn, G. Alastair Glendenning, Mark Sorensen, Stacie Hudgens, Brian Druker, François Guilhot, Richard A. Larson, Stephen G. O’Brien, Deborah Dobrez, Martee L. Hensley, David Cella
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial
Arndt Vogel, Shukui Qin, Masatoshi Kudo, Yun Su, Stacie Hudgens, Tatsuya Yamashita, Jung‐Hwan Yoon, Lætitia Fartoux, Krzysztof Simon, Carlos López, Max W. Sung, Kalgi Mody, Tatsuroh Ohtsuka, Toshiyuki Tamai, L. Michelle Bennett, Genevieve Meier, Valery Breder
Atherosclerotic risk factor reduction in peripheral arterial disease
Mary Mcdermott, Elizabeth A. Hahn, Philip Greenland, David Cella, Judith K. Ockene, Donna Brogan, William H. Pearce, Alan T. Hirsch, Kendra Hanley, Linda Odom, Shaheen Khan, Michael H. Criqui, Martin S. Lipsky, Stacie Hudgens